Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

To join this study, you need to be an adult (18 or older) who has had non-small cell lung cancer that was fully removed by surgery. Your cancer must have been classed as Stage II or IIIB before treatment. It's also very important that your cancer cells have a specific genetic change called an activating HER2 mutation. You would have already received standard treatments around the time of your surgery, like chemotherapy, and possibly immunotherapy.

There are also some general health requirements. For example, you need to be generally well enough to take part, as assessed by your doctor (often called having a good 'performance status') and your body's organs must be working properly based on blood tests. Women who can have children must agree to use effective birth control during the study.

However, you wouldn't be able to join if your lung cancer has other specific genetic changes that can be treated with different targeted therapies (like EGFR or ALK mutations). You also can't have had certain other conditions, like specific lung diseases, severe infections, or major surgery too recently before the study. Your study doctor will review all your medical information carefully to see if this study is right for you.

If you join this study, you'll be randomly assigned to one of two groups, like flipping a coin. You'll either receive the new medicine, zongertinib, which is a daily tablet taken for up to three years, or you'll receive the standard care, which could be another approved treatment given after surgery (called immunotherapy) or simply close monitoring (active surveillance). The choice for standard care depends on what your local doctors would typically recommend based on your situation.

Throughout the study, you'll have regular visits to the clinic so doctors can monitor your health, check for any side effects, and see how you're feeling. You'll likely have blood tests, scans, and fill out questionnaires about how you're doing. The researchers will track if your cancer comes back and your overall health. The total duration of your participation will depend on the treatment course, but you will be followed up to track how you are doing.